BARDA seeks 2-PAM autoinjectors for nerve agent antidote stockpile.
The Biomedical Advanced Research and Development Authority (BARDA), under the Department of Health and Human Services, is soliciting proposals for the procurement of 2-PAM Autoinjectors for Project Bioshield. The requirement includes the manufacture and delivery of autoinjectors containing pralidoxime chloride (2-PAM), an antidote for nerve agent poisoning, to support the Strategic National Stockpile. Offerors must demonstrate capability to produce FDA-approved autoinjectors and comply with cGMP. The contract is expected to be a multi-year, indefinite-delivery/indefinite-quantity (IDIQ) with a total value potentially exceeding $10 million. Performance will be in Washington, D.C., with delivery to various stockpile locations.